Comment

  • 6 July 2017

    Merck’s Keytruda stumbles in multiple myeloma

    On 5 July, Merck & Co. announced that the FDA had placed clinical holds on three combination studies of its programmed cell death protein 1 (PD-1) inhibitor, Keytruda (pembrolizumab), in...

  • 27 June 2017

    EHA 2017: BCl-2 as an Emerging Target for AML

    At the 2017 Annual European Hemophilia Association (EHA) meeting held between the 21st and the 25th of June in Madrid, Spain, many lectures focused on what is becoming one of...

  • 27 June 2017

    EHA 2017: Novartis is Leading the CAR-T Cell Race

    On June 24th, at the 2017 European Hematology Association (EHA) annual meeting in Madrid, Spain, an updated interim analysis from Novartis’ ELIANA trial was presented. ELIANA is the first global...

Close
Close
Close

Go Top